drugset / Trial / NCT05259020

To Evaluate the Pharmacokinetics and the Safety of ID14009 Compared to Coadministration of ID1805 With ID1803 in Healthy Adult Volunteers

NCT05259020

Phase 1 Unknown 60 enrolled IlDong Pharmaceutical Co Ltd
RandomizedCrossoverOpen-labelTreatment

Summary

To evaluate the pharmacokinetics and the safety of ID14009 compared to coadministration of ID1805 with ID1803 in healthy adult volunteers.

Timeline

Start
2022-02-22
Primary completion
2022-03-30
Completion
2022-03-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Amlodipine Other / unclassified 10 mg
Subject Ezetibmibe Unknown 10 mg
Subject Rosuvastatin Small molecule 20.8 mg
Subject Valsartan Small molecule 160 mg